Charles Gersbach and his colleagues are pursuing promising CRISPR technologies focused on controlling gene activity rather ...
Live Science on MSN
$3 million prize goes to duo whose research led to first sickle cell CRISPR therapy
Dr. Swee Lay Thein and Dr. Stuart Orkin won the $3 million Breakthrough Prize in Life Sciences for their work toward a ...
Victoria Gray, the first person cured of sickle cell using CRISPR gene editing therapies, spoke in Fargo about her journey and the need to lower the $2M treatment cost. Victoria Gray, cured of sickle ...
Sidra Medicine, a member of Qatar Foundation, has been qualified by Vertex Pharmaceuticals as one of a of a limited number of ...
For years, researchers have been trying to figure out how to treat inherited blood disorders like sickle cell disease without causing new health problems in the process. Now, a team of scientists from ...
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
—Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment— ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), ...
CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech company, achieved a major milestone when it earned approval for the ...
Hosted on MSN
Gene therapy for sickle cell and β-thalassemia works by disrupting three-dimensional genome structure
Scientists at St. Jude Children's Research Hospital and Northwestern University identified a previously unknown treatment opportunity for sickle cell disease and β-thalassemia. The discovery, ...
LINCOLN, Neb. (KOLN) - Groundbreaking advancements in Sickle Cell treatment are changing and saving lives nationwide. For decades, patients with Sickle Cell Disease have lived with pain, complications ...
Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset ...
Novo Nordisk’s etavopivat elicited a 27% drop in vaso-occlusive crises and 48.7% hemoglobin response after 24 weeks, creating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results